Cobra Biologics and Alligator Bioscience AB Sign Monoclonal Antibody Manufacturing Agreement
News Jun 19, 2012
Cobra Biologics and Alligator Bioscience AB have announced that they have entered into a manufacturing services and supply agreement for the production of monoclonal antibody Drug Substance and Drug Product for pre-clinical studies and Phase I-II clinical trials.
Under the terms of the agreement, Cobra will be providing cell line development through its maxXpress service, GMP cell banking, analytical and process development, scale-up, toxicology and GMP supplies, as well as stability studies and QP release for clinical trials.
Peter Coleman, CEO of Cobra Biologics said: "Having been through a rigorous selection process, we are very pleased to have been chosen by Alligator. We believe that our comprehensive service offering, right from our excellent cell line development capability through to fill/finish at our recently acquired Matfors facility (Sweden) enabled us to win this important program with Alligator in a highly competitive market place. We look forward to building a lasting relationship with Alligator Bioscience.”
Alligator will be taking advantage of Cobra’s maxXpress service, which combines the UCOE protein expression technology with the experience and expertise of Cobra Biologics’ cell line development team and the Cello™ robotic clone selection system, to enable rapid clone selection and production of the monoclonal antibody.
Arsenic Trioxide Could Extend Lives of Patients with Aggressive Brain CancerNews
Arsenic trioxide could be a powerful therapy that could extend the lives of certain glioblastoma patients by as much as three to four times the median expectation.READ MORE
XenoGesis and Juniper Pharma Services Strengthen AllianceNews
Campanies extend strategic alliance in early drug development services.READ MORE